Cancer-keeper genes as therapeutic targets.
Cancer
Drugs
Therapeutics
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
18 Aug 2023
18 Aug 2023
Historique:
received:
17
01
2023
revised:
18
05
2023
accepted:
03
07
2023
medline:
31
7
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
epublish
Résumé
Finding cancer-driver genes has been a central theme of cancer research. We took a different perspective; instead of considering normal cells, we focused on cancerous cells and genes that maintained abnormal cell growth, which we named cancer-keeper genes (CKGs). Intervening CKGs may rectify aberrant cell growth, making them potential cancer therapeutic targets. We introduced
Identifiants
pubmed: 37520717
doi: 10.1016/j.isci.2023.107296
pii: S2589-0042(23)01373-1
pmc: PMC10382876
doi:
Types de publication
Journal Article
Langues
eng
Pagination
107296Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
No potential conflicts of interest were disclosed.
Références
Mol Cancer Ther. 2015 Jan;14(1):174-82
pubmed: 25349305
Genome Biol. 2005;6(1):R2
pubmed: 15642094
Sci Rep. 2013 Oct 02;3:2650
pubmed: 24084849
Nat Commun. 2019 Feb 13;10(1):733
pubmed: 30760718
Nat Commun. 2013;4:2002
pubmed: 23774965
Nature. 2019 Apr;568(7753):511-516
pubmed: 30971826
PLoS One. 2013 Nov 25;8(11):e79397
pubmed: 24282504
Cell Res. 2020 Aug;30(8):660-669
pubmed: 32467592
Cancer Res. 2014 Jun 1;74(11):3114-26
pubmed: 24755469
Nat Commun. 2015 Oct 01;6:8414
pubmed: 26423222
Nature. 2011 May 12;473(7346):167-73
pubmed: 21562557
Cancer Cell. 2007 Sep;12(3):201-14
pubmed: 17785202
Cell. 1997 Feb 7;88(3):323-31
pubmed: 9039259
World J Urol. 2007 Dec;25(6):563-71
pubmed: 17710407
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D428-32
pubmed: 15608231
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
Nat Rev Genet. 2011 Jan;12(1):56-68
pubmed: 21164525
Sci Rep. 2017 Sep 6;7(1):10677
pubmed: 28878394
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Proteomics. 2004 Jun;4(6):1551-61
pubmed: 15174125
Sci Rep. 2017 Sep 4;7(1):10327
pubmed: 28871116
J Hum Genet. 2018 Sep;63(9):941-943
pubmed: 29907874
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Brief Bioinform. 2020 Sep 25;21(5):1641-1662
pubmed: 31711128
Trends Genet. 2013 Oct;29(10):569-74
pubmed: 23810203
Sci Rep. 2016 Nov 30;6:38209
pubmed: 27901102
Science. 2014 Mar 21;343(6177):1373-6
pubmed: 24653036
Gastroenterology. 2015 Oct;149(5):1226-1239.e4
pubmed: 26099527
Cell Prolif. 2003 Jun;36(3):131-49
pubmed: 12814430
Curr Mol Med. 2010 Jun;10(4):374-80
pubmed: 20455854
Nucleic Acids Res. 2021 Apr 19;49(7):e37
pubmed: 33434272
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
Methods Mol Biol. 2009;563:123-40
pubmed: 19597783
Nucleic Acids Res. 2009 Jan;37(Database issue):D674-9
pubmed: 18832364
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
BMC Syst Biol. 2009 Jun 15;3:61
pubmed: 19527511
Contemp Oncol (Pozn). 2015;19(1A):A68-77
pubmed: 25691825
Cell. 2012 Jul 20;150(2):251-63
pubmed: 22817889
Curr Cancer Drug Targets. 2012 Feb;12(2):85-96
pubmed: 22165965
Proteins. 2021 Jun;89(6):721-730
pubmed: 33550612
Nat Rev Drug Discov. 2002 Sep;1(9):727-30
pubmed: 12209152
Nature. 2020 Oct;586(7827):120-126
pubmed: 32968282
Cancer Lett. 2019 Aug 28;458:39-45
pubmed: 31125640
Wiley Interdiscip Rev Syst Biol Med. 2017 Jan;9(1):
pubmed: 27863091
Curr Mol Pharmacol. 2016;9(3):242-251
pubmed: 26177642
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
Science. 1991 Jul 5;253(5015):49-53
pubmed: 1905840
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Genome Res. 2012 Aug;22(8):1589-98
pubmed: 22759861
Nat Biotechnol. 2020 Feb;38(2):233-244
pubmed: 31907405
Oncotarget. 2017 Jul 25;8(30):50252-50272
pubmed: 28477017
Cancer Res. 2020 Nov 15;80(22):4986-4997
pubmed: 32973082
Proc Natl Acad Sci U S A. 2016 May 3;113(18):4976-81
pubmed: 27091990
Curr Med Chem. 2015;22(2):237-63
pubmed: 25386824